Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

IMPORTANCE: Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies. OBJECTIVE: To assess the efficacy and safety of a combination of pembrolizumab with bevacizumab and o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA Oncol
Prif Awduron: Zsiros, Emese, Lynam, Sarah, Attwood, Kristopher M., Wang, Chong, Chilakapati, Shanmuga, Gomez, Eduardo Cortes, Liu, Song, Akers, Stacey, Lele, Shashikant, Frederick, Peter J., Odunsi, Kunle
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2020
Pynciau:
Original Investigation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7677872/
https://ncbi.nlm.nih.gov/pubmed/33211063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.5945
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg